Erratum to: Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index
نویسندگان
چکیده
The authors of the above mentioned paper would like to make the following amendment to the author affiliations. Kazumi Tagawa’s affiliation currently reads ‘‘Department of Surgery, Shioda Hospital, Katsuura City, Japan’’. The affiliation should read ‘‘Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan’’. Finally, the authors would like to make the following amendments to Fig. 2. The x-axis labels for both Fig. 2a and Fig. 2b currently read ‘‘Time from TACE refractory (years)’’. The labels should read ‘‘Time (years)’’. The corrected Fig. 2 is provided here.
منابع مشابه
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index
INTRODUCTION Transcatheter arterial chemoembolization (TACE) is the first-line treatment for intermediate stage hepatocellular carcinoma (HCC) and prolongs survival in HCC patients. However, repeated TACE results in diminished therapeutic response. In addition, the superiority of sorafenib to TACE monotherapy or combined therapy in patients with HCC is still controversial. The prognosis of HCC ...
متن کاملThe effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7)
Objective(s): Hepatocellular carcinoma (HCC) is one of the most significant health condition around the world. As the only curative therapies, liver transplantation and surgical resection are the clinical treatments of HCC. Due to the systemic toxicity and severe side effects of these treatments, it is vital to establish new therapeutic approaches. The present study ai...
متن کاملLong-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
BACKGROUND/AIMS Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with advanced HCC with complete remission (CR) after sorafenib therapy. METHODS In total, 523 patien...
متن کاملEfficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis
Background The prognosis of hepatocellular carcinoma remains poor even after curative resection and it has no effective adjuvant therapy. Aim This meta-analysis aimed to assess efficacy of sorafenib as adjuvant therapy for patients with hepatocellular carcinoma after resection. Materials and methods A systematic search was conducted of Medline, Embase, Web of Science, Cochrane Library, Chin...
متن کاملEvaluation of Clinical, Demographic, Pathological, and Molecular Factors with Survival Rate of Patients with Oral Squamous cell Carcinoma in Yazd city During 1998–2008
Introdouction: Squamous cell carcinoma is the most common oral cancer and the prognosis because of a late diagnosis remains poor despite numerous treatments. Therefore, we conducted a cross-sectional study to investigate the relationships between survival rate(SR) of oral squamous cell carcinoma (OSCC) and clinical,demographic, pathological, and molecular factors in Yazd city during 1998–...
متن کامل